University Hospital Southampton NHS Foundation Trust

Accidental exposure to blood or other body fluids: risk assessment for post-exposure prophylaxis (PEP) with Hepatitis B Immunoglobulin (HBIG) and prescription form

Please note that UHS Pharmacy will issue HBIG only when both RISK ASSESSMENT FORM and PRESCRIPTION FORM are completed.

 Risk assessment form: page 1
 Prescription form: page 2

 FALSIFYING THIS RISK ASSESSMENT MAY RESULT IN A PATIENT RECEIVING HBIG INAPPROPRIATELY, PUTTING THEM AT

 UNNECESSARY RISK OF ANAPHYLAXIS.

 RISK ASSESSMENTS ARE RETROSPECTIVELY REVIEWED.

Risk Assessment to establish whether patient needs PEP with HBIG after accidental exposure to <u>blood</u> or <u>other body fluids</u>, from individuals who are HBsAg positive or at high-risk** to be HBsAg positive, through percutaneous inoculation or spillage into mouth/eyes or non-intact skin.

Exposure to blood (fresh blood dried blood) or to other body fluids (please specify) A1. → Percutaneous inoculation Deep Superficial Needlestick , (Hollow bore needle or Suture needle) Sharp Bite Scratches Yes → Spillage into mouth and/or eyes → Contact with non-intact skin (open wounds cezema dermatitis)	Box A. Assessment of kind*** and timing of exposure and of anti-HBs status of the exposed individual - Please check on the UHS's computer system if there is any previous records of the anti-HBs status of the exposed patient: (HBIG is unnecessary if the exposed individual has a record of anti-HBs level >100 IU/l = Protective Levels)						
Needlestick , (Hollow bore needle or Suture needle) Sharp Bite Scratches Yes) → Spillage into mouth and/or eyes)							
Sharp Bite Scratches Yes → Spillage into mouth and/or eyes							
→ Spillage into mouth and/or eyes							
	No						
→ Contact with non-intact skin (open wounds eczema dermatitis)							
A2. Is the date of exposure < than 7 days ago?							
A3. HBV vaccination history ≤ 1 dose of vaccine pre-exposure \Box <u>OR</u> known non-responder to HBV vaccine \Box <u>Yes</u> <u>No</u>							
***Significant exposure includes all percutaneous exposures and any mucocutaneous exposure to blood or blood stained body fluids.							
Box B. Assessment of the HBV status of the Source - Please check on the UHS's computer system if the donor's HBV status is already known. - If not, please send sources's serum sample to the UHS's Serology Laboratory (ext. 6342/6408)							

Name of the source		Date of birth NHS or Hospital		er			
B1. Is the Source HBsAg positive?						Yes	No
Please	e report the other H	HBV serological ma	arkers if availa	ble *			
HBeAg	POSITIVE	NEGATIVE	UNKNOWN	HBV DNA level (Viral Load)			
Anti-HBe	POSITIVE	NEGATIVE	UNKNOWN				
B2. Is the HBV status of the source unknown, but with a significantly high risk of being positive? **				N 7	у П		
Please state risk factors					Yes	No	

*Individuals with acute/chronic HBV infection are highly infectious if they are HBeAg positive and/or with high HBV VL. **For example the source is an Intravenous drug user (IVDU)

Risk assessment for administering HBIG

Performed by (block letters)	Doctor's signature			Date	
Designation	Department				
Patient's name	Patient's date of birth		Patient's hospital	number	
Home Address					
The following is required: Please tick					
All three YES answers froBo	x A		YES		NO
AND ONE YES answer	from Box B	YES			NO
			tes above are ticke requires HBIG	ed, the	

Dr Emanuela Pelosi, Consultant Virologist, Department of Infection, University Hospital Southampton NHS Foundation Trust: "HBIG, Risk assessment and Prescription forms", updated 10th March 2014.



Please note: HBIG is issued only when the UHS Pharmacy receives <u>HBIG</u> <u>PRESCRIPTION & the RISK ASSESSEMENT FORMS</u> (required for HBIG returns to the Department of Health Deliver or Fax (023 8120 6792) prescription and risk assessment forms to main dispensary Southampton General Hospital. If faxed, the original prescription will need to be received by pharmacy within 72 hours. Out of hours contact the Pharmacist on call through UHS switch board (Tel 023 80 777 222)

Prescription for Supply of Hepatitis B Immunoglobulin (HBIG) 500 IU for Post-Exposure Prophylaxis (PEP) (This form is not valid to prescribe HBIG to neonates)

Patient's Details			
Patient's Forename	Patient's Name	Hospital number	NHS number
Patient's address			

Product Details

Product (including form and strength where necessary)		Quantity in IU (for guidance see table below)		
	HBIG 500 IU			
Directions	Intramuscular injection	Deep subcutaneous injection in patients with bleeding disorders		
		Please state kind of bleeding disorder		
If HBV vaccine is administered at the same time, it should be injected at a different body site				

Authorisation (the person authorising is accountable for the risk assessment)

Name (in block letters)	Signature
Designation	Contact number
Ward/Surgery	Date

Collection/Delivery Method: Please check that arrangements are in place to have the injection(s) administered. Please specify					
Patient or Representative collecting	Taxi or Courier arranged by GP Surgery or Other Hospital	UHS Pharmacy can send the product to UHS A&E by prior arrangement (A&E phone No available through UHS switchboard). Please state name and contact details of A&E Nurse or Consultant with whom HBIG treatment administration has been agreed.			

Pharmacy Use Only Make sure that HBIG vials are stored within are the cold chain until use

Screened by	Dispensed by:	Checked by:	Product details:	Batch No	Date:
			HBIG		Essential record keeping Log details of this supply in the immunoglobulin register. Ensure one copy is
Cost code Stock loo		ocation	Volume to be	Expiry date	made (for the patient/healthcare professional) The original prescription and risk assessment
Inpatients: Ward			injected in ml		form needs to be filed in the IM
Outpatients: Patholog	gy SGH	SGH main dispensary			immunoglobulin folder. Please file appropriately immediately after checking

Dose of HBIG according to age:		Please Note:
0-4 yrs	200 IU	HBIG should be given by intramuscular injection as soon as possible, ideally within 48 hours (preferably within 12 hours) and not later than a week after exposure.
		 The administration of HBIG should be combined with simultaneous administration of HBV vaccine (accelerated vaccination schedule: doses spaced at zero, one and two months) at a different body site. HBV vaccine is available
5-9 yrs	300 IU	from SUHT Pharmacy but it is usually stocked in A&E, in Occupational Health, in the Neonatal Unit, in GP Surgeries and in Genitourinary Medicine
>10 yrs	500 IU	 Individuals who are known non-responder to HBV vaccine should receive a second dose of HBIG one month after the first dose, unless the source is shown to be HBsAg negative.

Dr Emanuela Pelosi, Consultant Virologist, Department of Infection, University Hospital Southampton NHS Foundation Trust: "HBIG, Risk assessment and Prescription forms", updated 10th March 2014.